Drugs / SAT-3247
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06565208 | Aug 2024 → Apr 2025 | Duchenne muscular dystrophy | Satellos Bioscience, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06867107 | Aug 2025 → Aug 2026 overdue | Duchenne muscular dystrophy | Satellos Bioscience, Inc. | Enrolling by invitation | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07287189 Comparator | Dec 2025 → Mar 2027 expected | Duchenne muscular dystrophy | Satellos Bioscience, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 18
| Date | Issuer | Release |
|---|---|---|
| 2026-08-13 | Satellos Bioscience, Inc. | Results Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress satellos.com ↗
Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regeneration |
| 2026-07-08 | Satellos Bioscience, Inc. | Results Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247 satellos.com ↗
The results, in four adults aged 21-28 who had previously completed the Phase 1a/b CL-101 study, showed reduced muscle fat fraction, increased total effort, stable strength, lower CK, and a safety and tolerability profile consistent with previously reported data. |
| 2026-06-29 | Satellos Bioscience, Inc. | Regulatory Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy satellos.com ↗
today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. |
| 2026-03-10 | Satellos Bioscience, Inc. | Results Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference satellos.com ↗ |
| 2025-12-09 | Satellos Bioscience, Inc. | Regulatory Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy satellos.com ↗
We are delighted to achieve U.S. and global clearance to start our Phase 2 pediatric study of SAT-3247, which we have named BASECAMP. |
| 2025-11-18 | Satellos Bioscience, Inc. | Results Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy satellos.com ↗
In the absence of dystrophin, researchers showed that muscle stem cells lose polarity and produce fewer myogenic progenitors, resulting in fewer and smaller muscle fibers. |
| 2025-10-10 | Satellos Bioscience, Inc. | Results Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy satellos.com ↗ |
| 2025-09-22 | Satellos Bioscience, Inc. | Regulatory Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy satellos.com ↗ |
| 2025-05-22 | Satellos Bioscience, Inc. | Results Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy satellos.com ↗
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated |
| 2025-03-19 | Satellos Bioscience, Inc. | Results Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference satellos.com ↗
Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration |
| 2024-10-01 | Satellos Bioscience, Inc. | Results Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels satellos.com ↗
Treated animals showed a return to muscle function near healthy, non-diseased, age-matched animal levels when evaluated against historical comparator data. |
| 2024-08-19 | Satellos Bioscience, Inc. | Regulatory Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247 satellos.com ↗ |
| 2024-08-12 | Satellos Bioscience, Inc. | Results Satellos Announces Q2 2024 Financial Results and Updated Canine Data satellos.com ↗
Today, we are proud to announce additional data from the now completed canine study in which we show that the interim positive effects on the function of muscle in these animals were further increased over the full four months of the study. |
| 2024-08-08 | Satellos Bioscience, Inc. | Regulatory Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy satellos.com ↗ |
| 2024-07-11 | Satellos Bioscience, Inc. | Regulatory Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247 satellos.com ↗
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced submission on July 10, 2024, of a clinical research proposal to a Human Research Ethics Committee (HREC) in Australia seeking regulatory authorization under their Therapeutic Goods Administration’s (TGA’s) Clinical Trial Notification (CTN) scheme to conduct a first-in-human Phase 1 clinical trial of SAT-3247. |
| 2024-07-02 | Satellos Bioscience, Inc. | Results Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”) satellos.com ↗
After treatment with SAT-3247 the animals showed an increase in Regenerative Index (RI), a measure of the number of newly regenerated muscle fibers versus the number of damaged and dying muscle fibers. |
| 2024-03-04 | Satellos Bioscience, Inc. | Results Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference satellos.com ↗
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration. |
| 2024-02-13 | Satellos Bioscience, Inc. | Results Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy satellos.com ↗
announced today positive preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of facioscapulohumeral muscular dystrophy (FSHD). |
All press releases naming this drug 27 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAT-3247 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06867107 ↗ |
| Action | Inhibit | “small molecule inhibitor of AAK1” NCT06565208 ↗ |
| Modality | Small molecule | “small molecule inhibitor of AAK1” NCT06565208 ↗ |
| Route | Oral | “SAT-3247 is an oral tablet” NCT06565208 ↗ |
| Target | AAK1 | “small molecule inhibitor of AAK1” NCT06565208 ↗ |